Mentice (MNTC) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
26 Feb, 2026Executive summary
Q4 2025 saw strong organic growth in net sales and order intake, driven by MDI customers in the Americas and APAC, despite significant negative currency effects and macroeconomic uncertainty.
EBITDA margin improved to 25% in Q4, with EBITDA at SEK 23 million, supported by higher sales, cost-saving measures, and strategic realignment.
Strategic focus remains on expanding the MDI segment, especially in the Americas and APAC, while EMEA stabilized; physical simulation business consolidated in Denver to improve efficiency.
Board changes and a rights issue occurred, with Gulf Offshore Limited increasing its stake, signaling further growth focus.
Full-year results were negatively impacted by FX and restructuring costs, but momentum improved in H2.
Financial highlights
Q4 net sales: SEK 90.8 million (17.6% organic growth); full-year net sales: SEK 279.1 million (3.4% organic growth, -3.9% YOY, -7.3% currency effect).
Q4 order intake: SEK 127 million (25% organic growth); full-year order intake: 8% organic growth (2% FX-adjusted).
Q4 EBITDA: SEK 23 million (margin 24.8%), net income: SEK 13 million, EPS: 0.46 SEK.
Full-year EBITDA: SEK 3.4 million (margin 1.2%), net income: -32.3 million, EPS: -1.15 SEK; adjusted EBITDA (excluding realignment costs): SEK 10.9 million.
Operational cash flow was negative for the year due to higher working capital and accounts receivables from increased sales; cash at year-end: SEK 33.4 million.
Outlook and guidance
Entering 2026 with a strong project pipeline, improved cost structure, and strategic focus on MDI and HCS segments.
Cost base expected to remain stable in 2026, with only minor, revenue-linked investments.
R&D investments to remain flat as a percentage of sales, focusing on advanced simulation, AI, and VR/AR technologies.
Targeting 20–30% annual net sales growth and 20% EBITDA margin within three years.
Macroeconomic uncertainty, currency volatility, and potential tariffs remain key challenges.
Latest events from Mentice
- Strong Q4 growth, expanded customer base, and focus on advanced simulation drive future outlook.MNTC
DNB Carnegie Healthcare Seminar 20269 Mar 2026 - Q3 sales fell nearly 10% year-over-year, but major new orders and APAC growth support the outlook.MNTC
Q3 202416 Jan 2026 - Q4 net sales up 22.4% with margin expansion, but full-year profit remained negative.MNTC
Q4 202424 Dec 2025 - Net sales up 19.5% year-over-year; losses and FX headwinds offset gains; strategic changes underway.MNTC
Q1 202520 Nov 2025 - Sales and order intake fell sharply, but restructuring and new clearances support future growth.MNTC
Q2 202516 Nov 2025 - Q3 revenue up 22% with margin gains, strong MDI growth, and improved net income.MNTC
Q3 20256 Nov 2025 - Record Q2 sales and profitability achieved, driven by strong APAC and Americas performance.MNTC
Q2 202413 Jun 2025